Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Short Interest Up 54.2% in February

Estrella Immunopharma, Inc. (NASDAQ:ESLAW) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 26,312 shares, an increase of 54.2% from the January 29th total of 17,060 shares. Based on an average daily volume of 5,539 shares, the short-interest ratio is presently 4.8 days. Based on an average daily volume of 5,539 shares, the short-interest ratio is presently 4.8 days.

Estrella Immunopharma Trading Down 5.0%

Shares of ESLAW stock opened at $0.08 on Friday. Estrella Immunopharma has a fifty-two week low of $0.03 and a fifty-two week high of $0.24. The stock has a 50 day simple moving average of $0.06 and a two-hundred day simple moving average of $0.07.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.